

# POSTER PRESENTATIONS

## POSTER SESSION 1: Thursday, November 5<sup>th</sup>

### THEME 1: Clinical Trials Methodology

- P1-1** **VALIDATING THE PGSA (PLACEBO GROUP SIMULATION APPROACH) USING DATA FROM A COMPANY-SPONSORED MCI DRUG TRIAL**  
René Spiegel PhD<sup>1</sup>, Andreas U. Monsch PhD<sup>1</sup>, André Miserez MD<sup>2</sup>, Manfred Berres PhD<sup>3</sup>  
<sup>(1)</sup> Felix Platter Hospital, University Center for Medicine of Aging Basel, Switzerland; <sup>(2)</sup> Diogene Laboratories Inc., Reinach, Switzerland; <sup>(3)</sup> University of Applied Sciences Koblenz, RheinAhrCampus, Remagen, Germany
- P1-2** **COMPARATIVE TRADITIONAL PSYCHOMETRICS OF COGNITIVE AND FUNCTIONAL ENDPOINTS IN A PRODRIMAL ALZHEIMER'S DISEASE POPULATION**  
Chris Edgar, PhD (1), Angela J Rylands, PhD, CPsychol (1), Dietmar Volz, PhD (2), Michaela Mertes (2), Elisabeth Gruendl, PhD (2), Paulo Fontoura, MD, PhD (2), Luca Santarelli, MD (2), Robert Lasser, MD, MBA (2)  
(1) Roche Products Limited, Welwyn Garden City, UK; (2) F. Hoffmann-La Roche Ltd, Basel, Switzerland
- P1-3** **DESIGNING A FIRST INTERVENTIONAL PHASE 2A TRIAL IN FTD-GRN WITH AN HDAC INHIBITOR (FRM-0334)**  
Hans J Moebius, MD, PhD (1), Nancy Dgetluck, MS (1), Gordon Loewen, PhD (1), Holger Patzke, PhD (1), Adam L Boxer, MD, PhD (2), Dana C Hilt, MD (1)  
(1) FORUM Pharmaceuticals Inc, Waltham, MA, USA; (2) Neurosciences Clinical Research Unit, University of California, San Francisco, CA, USA
- P1-4** **CAUSAL ANALYSIS WITH TRUNCATION BY DEATH IN RANDOMIZED AND NON-RANDOMIZED CLINICAL TRIALS**  
Xiao-Hua Zhou (1,2,3), Linbo Wang (1)  
(1) Department of Biostatistics, University of Washington, Seattle, WA, USA.; (2) National Alzheimer's Coordinating Center (NACC), University of Washington, Seattle, WA, USA; (3) Biostatistics Unit, U.S. Department of Veterans Affairs Seattle Medical Center, Seattle, WA, USA
- P1-5** **EXPERIENCES AND PERSPECTIVES OF STUDY PARTNERS INVOLVED IN DEMENTIA RESEARCH**  
Betty S. Black, PhD (1), Holly A. Taylor, PhD (2), Peter V. Rabins, MD (3), Jason Karlawish, MD (4)  
(1) Department of Psychiatry & Behavioral Sciences, Johns Hopkins School of Medicine and the Johns Hopkins Berman Institute of Bioethics, Baltimore, MD, USA; (2) Department of Health Policy & Management, Johns Hopkins School of Public Health and the Johns Hopkins Berman Institute of Bioethics, Baltimore, MD, USA; (3) Department of Psychiatry & Behavioral Sciences, Johns Hopkins School of Medicine and the Johns Hopkins Berman Institute of Bioethics, Baltimore
- P1-6** **FUNDACIÓ ACE HEALTHY BRAIN INITIATIVE (FACEHBI): A LONGITUDINAL STUDY OF BIOMARKERS AND COGNITION IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE**  
O. Rodríguez-Gómez (1) MD, A. Sanabria (1) MS, A. Pérez-Cordón (1) MS, S. Ruiz (1), M. Tarragona (1), D. Sánchez-Ruiz (1) MD, S. Moreno-Grau (1) MS, J. Pavía (2) PhD, F. Campos (2) MS, A. Vivas (3) MD, M. Gómez (3) MD, M. Tejero (3) RT, M. Alegret (1) PhD, A. Espinosa (1) MS, G. Ortega (1) PhD, C. Abdelnour (1) MD, M. Rosende-Roca (1) MD, A. Mauleón (1) MD, L. Vargas (1) MD, E. Martín (1) MS, S. Valero (1) PhD, O. Sotolongo-Grau (1) PhD, A. Ruiz (1) MD PhD, I. Hernández (1) MD, Phd, J. Giménez (3) MD, F. Lomeña (2) MD, L.Tárraga (1) MS, M. Boada (1) MD PhD  
(1) Alzheimer Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain; (2) Servei de Medicina Nuclear, Hospital Clínic i Provincial. Barcelona, Spain; (3) Departament de Diagnòstic per la Imatge. Clínica Corachan, Barcelona, Spain
- P1-7** **DEVELOPMENT OF A COGNITIVE SAFETY INDEX FOR MONITORING ADVERSE EVENTS IN INDIVIDUALS TAKING PART IN CLINICAL TRIALS OF ANTI-AMYLOID DRUGS**  
Paul Maruff, Yen Ying Lim (1,2), Peter J. Snyder (2), Víctor L. Villemagne (1,6,7), David Ames (8,9), Christopher C. Rowe (6,7), Robert Pietrzak, Colin L. Masters (1)  
(1) The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia; (2) Department of Neurology, Warren Alpert School of Medicine of Brown University & Lifespan Hospital System, Providence, RI, USA; (3) Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australia; (4) Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia; (5) Co-operative Research Centre for Mental Health, <http://www.mentalhealthcrc.com>; (6) Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia; (7) Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia; (8) Academic Unit for Psychiatry of Old Age, St. Vincent's Health, The University of Melbourne, Kew, Victoria, Australia; (9) National Ageing Research Institute, Parkville, Victoria, Australia; (10) CogState Ltd., Melbourne, Victoria, Australia
- P1-8** **SIMAMCI: A RANDOMIZED CONTROLLED TRIAL OF SIMVASTATIN IN AMNESTIC MCI PATIENTS FOR THE PREVENTION OF CONVERSION TO ALZHEIMER'S DEMENTIA**  
Brigitte Haas, PhD, Arne Klostermann, Oliver Peters, MD, Isabella Heuser, MD, PhD  
Department of Psychiatry, Charité University Medicine Berlin, Berlin, Germany

# POSTER PRESENTATIONS

## POSTER SESSION 1: Thursday, November 5<sup>th</sup>

- P1-9** **ANALYSING TIME TO EVENT DATA IN DEMENTIA PREVENTION TRIALS: THE EXAMPLE OF THE GUIDAGE STUDY OF EGB761®**  
SCHERRER B (1), ANDRIEU S (2,3,4,5), OUSSET P-J (2,3,4), G BERRUT (6), DARTIGUES J-F (7), DUBOIS B (8), PASQUIER F (9), PIETTE F (10), ROBERT P (11), TOUCHON J (12), GARNIER P (13), MATHIEX-FORTUNET H (13), VELLAS B (2,3,4), and the GuidAge Study Group\*  
(1) Bruno Scherrer Conseil, Saint-Arnoult en Yvelines, France; (2) INSERM, U1027, Toulouse, France; (3) University of Toulouse III, Toulouse, France; (4) Gerontopole, Toulouse University Hospital, Toulouse, France; (5) Department of Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France; (6) Clinical Gerontology Department, Nantes University Hospital, Nantes, France; (7) INSERM U897, University of Bordeaux II, Bordeaux, France; (8) Department of Neurology and Alzheimer Institute, Salpêtrière University Hospital, Paris, France; (9) University Lille Nord de France, UDSL EA1046, Centre Hospitalier Universitaire, Lille, France; (10) Gerontology Department, Charles Foix Hospital, Pierre and Marie Curie University, Ivry-sur-Seine, France 11Memory Center–EA CoBTeK Centre Hospitalier Universitaire, University of Nice Sophia Antipolis, Nice, France 12 Neurology Department, INSERM U1061, Montpellier University Hospital, Montpellier, France 13Ipsen, Boulogne, France
- 
- P1-10** **INFLAMMATORY MARKERS IN ALZHEIMER'S DISEASE WITH VARIOUS DEGREES OF DEMENTIA SEVERITY**  
Tatyana Klyushnik, Lyubov Androsova, Natalia Mikhaylova, Svetlana Zozulya, Alexander Dupin, Svetlana Gavrilova  
FSGI "The Mental Health Research Centre", Moscow, Russia
- 
- P1-11** **STATISTICAL PROPERTIES OF COMPOSITE SCALES**  
Hong Liu-Seifert, PhD (1), Scott Andersen, MS (1), Michael Case, MS (1), JonDavid Sparks, PhD (1), Suzanne Hendrix, PhD (2), Paul Aisen, MD (3), Eric Siemers, MD (1)  
(1) Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; (2) Pentara Corporation, Salt Lake City, UT, USA; (3) Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA
- 
- P1-12** **APPLICATION OF NEUROCIRCUITRY-BASED ASSESSMENTS USING EEG/ERP AND FMRI TO ASSESS NOVEL MOLECULES IN EARLY PHASE CLINICAL DEVELOPMENT FOR BEHAVIOURAL AND PSYCHIATRIC SYMPTOMS ASSOCIATED WITH DEMENTIA**  
Brett A. English, PharmD, PhD (1,2), Jack Johnstone, PhD (3), Alex Korb, PhD (4), Lev Gertsik, MD (5), Lovingly Q. Park, PhD (5), Niki Osimo (1), Larry Ereshefsky, PharmD (1,6)  
(1) PAREXEL International Glendale, CA; (2) Dept. of Pharmacology, Vanderbilt University Medical Center, Nashville, TN; (3) Q-Matrix, Glendale, CA; (4) Department of Psychiatry, University of California, Los Angeles; (5) California Clinical Trials Medical Group, Glendale, CA; (6) University of Texas College of Pharmacy, Austin, TX; Glendale, CA
- 
- P1-13** **ENHANCING CLINICAL TRIAL RECRUITMENT IN ALZHEIMER'S DISEASE RESEARCH THROUGH MOBILE CLINICAL TRIAL UNIT**  
Jill Smith, MA, CCRC (1); Amanda Smith, MD (1), Dave Morgan, PhD (1)  
(1) USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa FL USA
- 
- P1-14** **A METHODOLOGY FOR EVALUATING CLINICAL TRIAL SITES AND RATERS BASED ON PERFORMANCE DATA**  
Miller, D (1), Feaster, T (1), Allen, S (1), Gratkowski, H (1), Butler, A (1)  
(1) Bracket, Wayne, PA, USA
- 
- P1-15** **EFFICIENCY OF TELEPHONE PRESCREENING FOR THE A4 TRIAL**  
Kristine Lipowski (1), Okkes Kuybu (1), Carly Oboudiyat (1), Raj C. Shah (2), Neelum T. Aggarwal (2), Sandra Weintraub (1)  
(1) Northwestern University Cognitive Neurology and Alzheimer's Disease Center, Chicago, IL; (2) Rush Alzheimer's Disease Center, Chicago, IL
- 
- P1-16** **ASSESSING ELIGIBILITY FOR PRODROMAL AND PRECLINICAL AD TRIALS USING THE LUMOSITY BRAIN PERFORMANCE TEST AND THE BRAIN HEALTH REGISTRY**  
Rachel L Nosheny PhD (1), Derek Flenniken (1), Philip S Insel (1), R Scott Mackin PhD (1,2), Shannon Finley (1), Monica Camacho (1), Diana Truran (1), Glenn Morrison PhD (3), Nicole Ng (3), Daniel Sternberg PhD (3), Michael W Weiner MD,(1,4)  
(1) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran's Administration Medical Center, San Francisco, CA; (2) UCSF Department of Psychiatry, San Francisco, CA; (3) Lumos Labs. Inc. San Francisco, CA; (4) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA
- 
- P1-17** **DEVELOPMENT OF AD CLINICAL RESEARCH: EXAMPLE OF THE NORTH OF FRANCE MEMORY CLINICS NETWORK "MEOTIS3RC"**  
Catherine Adnet-Bonte, MD (1), Laetitia Breuilh, PhD (2,3), Florence Pasquier, MD, PhD (2,3)  
(1) Meotis, Centre Hospitalier Regional Universitaire de Lille, France; (2) Neurology Department, Centre Hospitalier Regional Universitaire de Lille, France; (3) Excellence Laboratory DISTALZ
-

## POSTER SESSION 1: Thursday, November 5<sup>th</sup>

### THEME 2: Clinical Trials Results

- P1-18 EFFECTS OF MULTIMODAL COGNITIVE ENHANCEMENT THERAPY (MCET) FOR PEOPLE WITH MILD COGNITIVE IMPAIRMENT AND EARLY STAGE DEMENTIA: A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, CROSS-OVER TRIAL**  
Ji Won Han, MD (1), Hyeonggon Lee, MD (2), Jong Woo Hong, MD (1), Kayoung Kim, MD (1), Tae Hyun Kim, MD (1), Hye Jin Byun, (1) Ji Won Ko, (1) Jong Chul Yoon, MD, PhD (3), Seung-Ho Ryu, MD, PhD (4), Nam-Jin Lee, MD (5), Ki Woong Kim, MD, PhD (1,6,7)  
(1) Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea; (2) Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Korea; (3) Department of Neuropsychiatry, Kyunggi Provincial Hospital for the Elderly, Yongin, Korea, (4) Department of Psychiatry, School of Medicine, Konkuk University, Konkuk University Medical Center, Seoul, Korea; (5) Department of Psychiatry, Jeonju City Welfare Hospital for the Elderly, Jeonju, Korea; (6) Department of Brain and Cognitive Science, Seoul National University College of Natural Sciences, Seoul, Korea; (7) Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea
- P1-19 AN INTELLIGENT SYSTEM FOR MONITORING PEOPLE WITH DEMENTIA**  
Édgar Batista, Frederic Borràs, Antoni Martínez-Ballesté, Agusti Solanas  
Smart Health Research Group, Universitat Rovira i Virgili, Tarragona, Catalonia, Spain
- P1-20 PHASE I STUDIES EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE-RISING DOSES OF BI 409306 IN YOUNG AND ELDERLY HEALTHY VOLUNTEERS**  
Glen Wunderlich, PhD (1), Wolfgang Timmer, MD (2), Grit Andersen, MD (3), Anja Hoch (4), Viktoria Moschetti, MD (5), Katja Boland, PhD (4), Heike Zimdahl-Gelling, PhD (4), Andreas Borta MD, PhD (4), Michael Sand PhD, MPH (6)  
(1) Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada; (2) CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany; (3) Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany; (4) Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; (5) Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; (6) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
- P1-21 CUMULATIVE CLINICAL EFFICACY OF IDALOPIRDINE, A 5-HT<sub>6</sub> ANTAGONIST IN ADVANCED DEVELOPMENT FOR TREATMENT OF ALZHEIMER'S DISEASE**  
Alireza Atri, MD, PhD (1), Kristian Windfeld, PhD (2), Benoît Rive, PhD (3)  
(1) Ray Dolby Brain Health Center, California Pacific Medical Center, San Francisco, CA; Dept. of Neurology, Massachusetts General Hospital; and Harvard Medical School, Boston MA, USA; (2) H. Lundbeck A/S, Valby, Denmark; (3) Lundbeck SAS, Issy-les-Moulineaux, France
- P1-22 THE ROSAS STUDY: A LONG-TERM, LONGITUDINAL, MULTI-PARAMETRIC AND COMPARATIVE EVALUATION OF ALZHEIMER'S DISEASE PROGRESSION IN A UNIQUE COHORT OF PATIENTS**  
Pierre-Jean Ousset, MD (1), Maria Pueyo, MD (2), PhD, Maria Soto MD, (1), PhD, Vera Kiyasova, MD (2), PhD, Isabelle Guignot, MS (2), Eva Bouguen, MSc (2), Stéphanie Galtier, MSc (2), Fabrice Bonneville, MD (1), PhD, Françoise Lala, MD (1), Nathalie Sastre, MD (1), Julien Delrieu, MD (1), Bruno Vellas, MD (1), PhD  
(1) Gerontopôle, INSERM U 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, France; (2) Institute de Recherches Internationales SERVIER, Suresnes, France
- P1-23 PHARMACOKINETICS AND TARGET ENGAGEMENT PROFILE OF RESVERATROL IN HUMAN BLOOD: IMPLICATIONS FOR AD CLINICAL TRIALS**  
Louise Monte, MS (1,2), Darren Insko, PhD (1,2), Paula Desplats, PhD (2), Paul S. Aisen, MD (1,2), R. Scott Turner, MD, PhD (3), Robert A. Rissman, PhD (1,2)  
(1) Alzheimer's Disease Cooperative Study; (2) Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA; (3) Department of Neurology, Georgetown University, Washington, DC, USA
- P1-24 COGNITIVE AND FUNCTIONAL EFFICACY OF TRAMIPIROSATE IN APOE<sub>4</sub><sup>+</sup> PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE: SUBGROUP ANALYSES OF THE PHASE 3 NORTH AMERICAN AND EUROPEAN TRIALS**  
John A. Hey (1), Jeremy Yu (1), Martin Tolar (1), Menghis Bairu (2), John Sampalis (3)  
(1) Alzheon, Inc., Framingham, MA, USA; (2) Serenus Biotherapeutics, Inc., San Francisco, CA, USA; (3) JSS Medical Research, Inc., St. Laurent, QC, Canada & McGill University, Montreal, QC, Canada
- P1-25 DISEASE-MODIFYING EFFECT OF B-VITAMINS ON BRAIN ATROPHY AND COGNITIVE DECLINE IN MCI IS ENHANCED BY OMEGA-3 FATTY STATUS**  
A.D. Smith (1), A.Oulhaj (2), F. Jermeren (1), H. Refsum (1,3), C.A. de Jager (4)  
(1) OPTIMA, Department of Pharmacology, University of Oxford, Oxford, United Kingdom; (2) Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, United Arab Emirates; (3) Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; (4) Division of Geriatric Medicine, Department of Medicine, University of Cape Town, Cape Town, South Africa
- P1-26 HEALTHY AGEING THROUGH INTERNET COUNSELING IN THE ELDERLY (HATICE) – A LARGE PREVENTION TRIAL**  
E Richard, S Andrieu, H Soininen, C Brayne, N Coley, J Guillemont, F Mangialasche, T Ngandu, C Beishuizen, Y Meiller, A vd Groep, E Moll van Charante, WA van Gool, M Kivipelto  
Academic Medical Center, dept of Neurology, Amsterdam; INSERM U1027, University of Toulouse III; Dept. of Epidemiology and Public Health and Gerontopole, Toulouse University Hospital; Dept. of Neurology, University of Eastern Finland, Kuopio; Dept. of Public Health and Primary Care, Institute of Public Health, Cambridge, UK; NOVAPTEN; Aging Research Center, Dept. of Neurobiology, Health Care Sciences and Society, Karolinska Institute, Stockholm; Dept. of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki; VitalHealth Software; Academic Medical Center, dept of primary care, Amsterdam

# POSTER PRESENTATIONS

## POSTER SESSION 1: Thursday, November 5<sup>th</sup>

**P1-27 PHARMACOKINETIC AND PHARMACODYNAMIC (PK/PD) ASSESSMENT AND COVARIATE ANALYSIS FOR ADUCANUMAB (BIIB037) IN PATIENTS WITH PRODROMAL OR MILD ALZHEIMER'S DISEASE: INTERIM RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1B STUDY**  
Yaming Hang (1), PhD, Ping Chiao (1), PhD, Jeff Sevigny (1), MD, Leslie Williams (1), DVM, MPH, Xiaopeng Miao (1), PhD, John O'Gorman (1), PhD, Alvy Mikulskis (1), Kate Leitermann (1), James Ferrero (1), PhD  
(1) Biogen, Cambridge, MA, USA

**P1-28 COMPARATIVE EFFICACY AND SAFETY OF ANTIDEPRESSIVE MONO- AND MULTIMODAL THERAPY IN ELDERLY PATIENTS WITH DEPRESSION IN PSYCHOGERIATRIC HOSPITAL**  
Y.B. Kalyn, T.P. Safarova, V.S. Sheshenin, S.I. Gavrilova  
FSGI "The Mental Health Research Centre", Moscow, Russia

**P1-29 COGNITIVE RESPONSE TO METFORMIN IS ASSOCIATED WITH PRE-TREATMENT CSF A $\beta$ 1-42 LEVELS: SECONDARY ANALYSIS OF DATA FROM PILOT STUDY OF METFORMIN'S EFFECTS ON BIOMARKERS OF ALZHEIMER'S DISEASE**  
Aaron M. Koenig MD (1,2,5), David A. Wolk MD (1,3), Dawn Mechanic-Hamilton PhD (1,2), Sharon X. Xie PhD (4), Martha F. Combs MS (1,2), Steven E. Arnold MD (1,2,3,6)  
(1) Penn Memory Center, University of Pennsylvania, Philadelphia, PA, USA; (2) Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA; (3) Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA; (4) Department of Epidemiology & Biostatistics, University of Pennsylvania, Philadelphia, PA, USA; (5) Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA (Current affiliation); (6) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA (Current affiliation)

**P1-30 PREVENTION OF COGNITIVE DECLINE AND IMPROVEMENT OF INNATE IMMUNITY IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT BY OMEGA-3 FATTY ACID AND ANTI-OXIDANT SUPPLEMENTATION**  
M. Fiala, M.D  
Surgery Department, UCLA, Los Angeles, CA, USA

**P1-31 ACCELERATING PATIENT RECRUITMENT IN EARLY ALZHEIMER'S DISEASE**  
Hans Chr. Hoock, MD, PhD (1), Mette Skaksen (2), Tue K. Rasmussen, MD, PhD (2), Peter Alexandersen, MD, DMSc (3), Line M. Lindgren MD (4), Anthony Frankland (1), Roger Bullock, MD (1)  
(1) CCBR, Stans, NW, Switzerland; (2) CCBR, Aalborg, Denmark; (3) CCBR, Vejle, Denmark; (4) CCBR, Copenhagen, Denmark

### THEME 5: Clinical Trials and Cognitive Endpoints

**P1-32 EFFICIENCY OF COGNITIVE REHABILITATION IN ALZHEIMER'S DISEASE: A ONE YEAR FOLLOW-UP STUDY**  
Sophie Germain, PhD (1,2), Vinciane Wojtasik (1), Françoise Lekeu PhD (1), Anne Quittre (1), Catherine Olivier (1), Vinciane Godichard MA (1), Eric Salmon, MD, PhD (1,3)  
(1) Memory Clinic, Department of Neurology, C.H.U. Liège, Belgium; (2) Neuropsychology Unit, Department of Psychology: Cognition and Behavior, University of Liège, Belgium; (3) Cyclotron Research Centre, University of Liège, Belgium

**P1-33 CLINICAL CORRELATES OF COGNITIVE SCALES USED AS PRIMARY ENDPOINTS IN PRODROMAL ALZHEIMER'S DISEASE CLINICAL TRIALS**  
Steven D. Edland (1,2)  
(1) Department of Neurosciences, University of California San Diego, La Jolla, CA, USA; (2) Division of Biostatistics, Department of Family & Preventive Medicine, University of California San Diego, La Jolla, CA, USA

**P1-34 DAILY FUNCTIONING BENEFITS OF ADDING MEMANTINE TO STABLE CHOLINESTERASE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE: A POST HOC POOLED FACTOR ANALYSIS**  
Gustavo Alva, MD (1), Noel Ellison, MS (2), Biplob Dass, PhD (3), Suzanne Hendrix, PhD (2)  
(1) ATP Clinical Research, Costa Mesa, CA, USA; (2) Pentara Corporation, Salt Lake City, UT, USA; (3) Prescott Medical Communications Group, Chicago, IL, USA

**P1-35 IMPROVEMENT IN VISION, COGNITION, AND NEUROPSYCHIATRIC SYMPTOMS FOLLOWING CATARACT SURGERY IN SUBJECTS WITH DEMENTIA**  
Alan J. Lerner (1,4), Sara M. Debanne (2), Julie K. Belkin (3,4), Jonathan H. Lass (3,4), Paula K. Ogrocki (1,4), Tatiana M. Riedel (6), Susie A. Sami (4), Thomas L. Steinemann (3,5), Grover C. Gilmore (6)  
(1) Department of Neurology, Case Western Reserve University, Cleveland, OH, USA; (2) Epidemiology and Biostatistics Case Western Reserve University, Cleveland, OH, USA; (3) Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, OH, USA; (4) Department of Neurology, University Hospitals Case Medical Center, Cleveland, OH, USA; (5) Department of Ophthalmology, MetroHealth Medical Center, Cleveland, OH, USA; (6) Jack, Joseph and Morton Mandel School of Applied Social Sciences, Case Western Reserve University, Cleveland, OH, USA

**P1-36 THE ADAS-COG NAME ITEM: MORE TROUBLE THAN IT IS WORTH?**  
Selam Negash (1), Christopher Weber (1), Lori Garzio (1), Christopher Randolph (1,2)  
(1) MedAvante, Inc, (2) Loyola University Medical Center

# POSTER PRESENTATIONS

## POSTER SESSION 1: Thursday, November 5<sup>th</sup>

**P1-37 MEASURING EXECUTIVE FUNCTION USING A SIMPLE, CULTURE- AND EDUCATION-FREE TASK**  
Michael D. Lee, PhD (1), Melinea Abramyan (1), William R. Shankle, MS MD (1,2,3)  
(1) Dept. of Cognitive Sciences, University of California at Irvine, Irvine, CA, USA; (2) Medical Care Corporation, Irvine, CA, USA; (3) Hoag Neuroscience Institute, Hoag Memorial Hospital, Newport Beach, CA USA

**P1-38 AN INNOVATIVE COGNITIVE INTERVENTION GROUP PROGRAM FOR PATIENTS WITH MILD COGNITIVE IMPAIRMENT: TRAIN YOUR BRAIN**  
YanHong Dong, PhD (1,2), Kim A. Granland, MSc (2,3)  
(1) Psychological Medicine, National University Hospital, Singapore, (2) Memory Ageing and Cognition Center, Pharmacology, National University Health System, Singapore, (3) James Cook University, Singapore Campus, Singapore

**P1-39 IMPACT OF EXPERT DATA REVIEW AND CENTRALIZED SCORING ON TESTRETEST RELIABILITY OF THE ADASCOG**  
Alexandra S Atkins, PhD (1), Ioan Stroescu, PhD (1), Vicki G. Davis, DrPH (1), Tina Tseng, PhD (1), Tiffany Williamson, BA (1), Kelley Boyd, BS (1), Lyn Harper Mozley, PhD (2), Tiffini Voss, MD (2), Kerry BuddMcMahon (2), Richard SE Keefe, PhD (1,3)  
(1) NeuroCog Trials, Durham, NC, USA, (2) Merck & Co, Inc., Kenilworth, NJ, USA, (3) Duke University Medical Center, Durham, NC, USA

### THEME 6: Clinical Trials and Cognitive Assessments

**P1-40 CREATION OF A MOBILE RESEARCH TEAM TO ALLOW EQUAL OPPORTUNITY FOR PATIENTS WITH ALZHEIMER DISEASE**  
Emilie Chrétien, PhD (1); Jing Xie, MD (1); Christelle Mouchoux, MD (1); Pierre Krolak-Salmon, MD (1)  
(1) CRC VCF, Hôpital des Charpennes, Villeurbanne, France

**P1-41 EFFECT OF CIRCADIAN RHYTHM ON COGNITION TESTING IN A PHASE 2B MILD/MODERATE ALZHEIMER'S DISEASE (AD) STUDY4**  
Dana C Hill MD (1), Nancy Dgetluck, MS (1), Stephen Sainati, MD (1), Hans J Moebius, MD, PhD (1)  
FORUM Pharmaceuticals, Waltham MA, USA

**P1-42 THE IMPACT OF ELECTRONIC ADMINISTRATION OF THE ADAS-COG, MMSE AND CDR ON CLINICAL TRIAL DATA QUALITY**  
David Miller, MD, MA (1), Todd Feaster, Psy.D (1), Antonio Hernandez, Psy.D (1), Jessie He, MD (2), Alan Kott, MUDr (3)  
(1) Bracket, Wayne, PA, USA (2) F. Hoffmann-La Roche, Shanghai, China (3) Bracket, Prague, Czech Republic

**P1-43 THE INFLUENCE OF THE SUBCORTICAL ISCHEMIA AND COGNITIVE PATTERNS AND THEIR CHANGES IN NORMAL HOSPITAL VISITED ELDERLY**  
Sang Joon Ahn, MD (1), Bon D. Ku, MD (2), Hye-Yoon Kim, MD (2), Min Sung Koo, MD, PhD (3)  
(1) Neurology Department, Seoul National University, Seoul, South Korea; (2) Neurology Department, Catholic Kwandong University, Incheon, South Korea; (3) Psychiatry Department, Catholic Kwandong University, Incheon, South Korea

**P1-44 RELATIONSHIP BETWEEN SUBJECTIVE AND OBJECTIVE MEMORY IMPAIRMENT IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND NORMAL AGING**  
Montserrat Alegret, PhD (1), Octavio Rodríguez, MD (1), Ana Espinosa, MSc (1), Gemma Ortega, PhD (1), Angela Sanabria, MSc (1), Sergi Valero, PhD (1,2), Isabel Hernández, MD, PhD (1), Maitée Rosende-Roca, MD (1), Lilita Vargas, MD (1), Carla Abdelnour, MD (1), Ana Mauleón, MD (1), Anna Gailhajanet, MSc (1), Elvira Martín, MSc (1), Lluís Tárraga, MSc (1), Dorene M. Rentz, PsyD (3,4), Rebecca E. Amariglio, PhD (3,4), Agustín Ruíz, MD, PhD (1), Mercè Boada, MD, PhD (1)  
(1) Alzheimer Research Center and Memory Clinic of Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona, Spain; (2) Psychiatry Department. Hospital Universitari Vall d'Hebron, CIBERSAM. Universitat Autònoma de Barcelona, Spain; (3) Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; (4) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

**P1-45 REGIONAL WHITE MATTER DISRUPTIONS OF CINGULUM IN MILD COGNITIVE IMPAIRMENT DEFINED BY FUNCTIONAL AND COGNITIVE CRITERIA**  
Yu-Ling Chang, PhD (1,2), Yu-Shiuan Yen, MS (1), Pei-Cing Chen, MS (1), Chia-Hua Lin, BS (1), Yi-Yuan Zhuo BS (1), Ta-Fu Chen, MD (3), Sui-Hing Yan, MD (4), Wen-Yih Isaac Tseng, MD, PhD (2,5,6,7)  
(1) Department of Psychology, National Taiwan University, Taipei, Taiwan; (2) Neurobiology and Cognitive Science Center, National Taiwan University, Taipei, Taiwan; (3) Department of Neurology, National Taiwan University, Taipei, Taiwan; (4) Section of Neurology, Renai Branch, Taipei City Hospital, Taipei, Taiwan; (5) Graduate Institute of Medical Devices and Imaging System, National Taiwan University, Taipei, Taiwan; (6) Graduate Institute of Brain and Mind Sciences, National Taiwan University, Taipei, Taiwan; (7) Department of Medical Imaging, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan

**P1-46 Δ SCORES PREDICT AD CONVERSIONS FROM MCI. CASE-SELECTION FOR EARLY INTERVENTIONS**  
Donald R. Royall, MD (1-4), Raymond F. Palmer, PhD (3)  
(1) Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA; (2) Department of Medicine, UTHSCSA, San Antonio, Texas, USA; (3) Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA; (4) South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

# POSTER PRESENTATIONS

## POSTER SESSION 1: Thursday, November 5<sup>th</sup>

### **P1-47 DIFFERENTIAL EFFECTS OF VASCULAR AND AMYLOID PATHOLOGY ON COGNITIVE FUNCTIONS IN MILD COGNITIVE IMPAIRMENT**

Elena Rolandi, (1) Moira Marizzoni, (1) Samantha Galluzzi, (1) Jorge Jovicich, (2) Flavio Nobili, (3) Mira Didic, (4,5) David Bartrés-Faz, (6) Ute Fiedler (7), Peter Schonknecht (8), Pierre Payoux, (9,10) Alberto Beltramello, (11) Andrea Soricelli, (12,13) Lucilla Parnetti, (14) Magda Tsolaki, (15) Paolo Maria Rossini, (16,17) Philip Scheltens, (18) Gianluigi Forloni, (19) Regis Bordet, (20) Olivier Blin, (21) Giovanni Battista Frisoni, (1,22); on behalf of the PharmaCog Consortium  
(1) Laboratory of Neuroimaging and Alzheimer's Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; (2) Center for Mind/Brain Sciences, Dept. of Cognitive and Education Sciences, University of Trento, Trento, Italy; (3) Department of Neuroscience, Ophthalmology, Genetics and Mother-Child Health (DINOGLI), University of Genoa, Genoa, Italy; (4) APHM, CHU Timone, Service de Neurologie et Neuropsychologie, Marseille, France; (5) Aix-Marseille Université, INSERM U 1106, Marseille, France; (6) Department of Psychiatry and Clinical Psychobiology, Universitat de Barcelona and IDIBAPS, Barcelona, Spain; (7) LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany; (8) Department of Neuroradiology, University Hospital Leipzig, Leipzig, Germany; (9) INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse, France; (10) Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse, France; (11) Department of Neuroradiology, General Hospital, Verona, Italy; (12) IRCCS SDN, Naples, Italy; (13) University of Naples Parthenope, Naples, Italy; (14) Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy; (15) 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece; (16) Dept. Geriatrics, Neuroscience & Orthopaedics, Catholic University, Policlinic Gemelli, Rome, Italy; (17) IRCSS S.Raffaele Pisana, Rome, Italy; (18) Alzheimer Centre and Department of Neurology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands; (19) Neuroscience Department, IRCCS Istituto di Ricerche Farmacologiche «Mario Negri», Milano, Italy; (20) Department of Pharmacology, EA1046, University of Lille Nord de France, Lille Cedex, France; (21) Pharmacology, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University-CNRS UMR 7289, Marseille, France; (22) Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland

### **P1-48 ACEMOBILE – UTILIZING AN APP PLATFORM TO SUPPORT DEMENTIA RESEARCH VIA PARALLELED SUPPORT AND DATA ACQUISITION: AN UPDATE**

Craig Newman, PhD, DClinPsych (1), John Hodges, MD (2), Stephen Pearson, MD (3), Rupert Noad, MPhil, DClinPsych (4)  
(1) Plymouth University Peninsular Schools of Medicine and Dentistry, Plymouth, UK; (2) Neuroscience Research Australia, New South Wales, Australia; (3) Devon Partnership Trust, Devon, UK; (4) Plymouth Hospital NHS Trust, Plymouth UK

### **P1-49 THE SKT SHORT COGNITIVE PERFORMANCE TEST: A REGRESSION-BASED SCALING OF A PROVEN NEUROPSYCHOLOGICAL TEST ESPECIALLY FOR PRE-CLINICAL STAGES OF NEUROCOGNITIVE DISORDERS**

Mark Stemmler, PhD (1), Hartmut Lehfeld, PhD (2), Ralf Horn, PhD (3)  
(1) Friedrich-Alexander University (FAU) of Erlangen-Nuremberg, Germany; (2) Department of Psychiatry and Psychiatry, Nuremberg General Hospital, Germany; (3) Hornburg Inc., Germany

### **P1-50 NORMATIVE STUDY OF THE GERMAN LANGUAGE TOMMORROW NEUROPSYCHOLOGICAL BATTERY**

Brenda L. Plassman, PhD (1,2), Andreas Monsch, PhD (3), Kathleen A. Welsh-Bohmer, PhD (1,2), Heather Romero, PhD (1,2), Kathleen M. Hayden, PhD (1,2,4), Kumar Budur, MD (5), Grant Runyan, PhD (5), Stephen Crawford, PhD, MHS (6), Mark Atkinson, PhD (6), Toyoko Oguri (6), Alexandra Atkins, PhD (7), Nicole Turcotte, MA (7), Richard Keefe, PhD (7), Shyama Brewster (8), Daniel K. Burns, PhD (8), Allen D. Roses, MD (8) for the TOMMORROW study investigators  
(1) Joseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC, USA; (2) Department of Psychiatry, Duke University Medical Center, Durham, NC, USA; (3) University of Basel, Basel, Switzerland; (4) Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA; (5) Takeda Development Center Americas, Inc., Deerfield, IL, USA; (6) Covance Inc, Princeton, NJ, USA; (7) NeuroCog Trials Inc., Durham, NC, USA; (8) Zinfandel Pharmaceuticals, Inc., Chapel Hill, NC, USA

### **P1-51 NORMATIVE STUDY OF THE RUSSIAN TOMMORROW NEUROPSYCHOLOGICAL BATTERY**

Heather Romero (1,2), Oksana Makeeva (3), Kathleen A. Welsh-Bohmer (1,2), Brenda L. Plassman (1,2), Kathleen M. Hayden (1,2,4), Kumar Budur (5), Grant Runyan (5), Stephen Crawford (6), Mark Atkinson (6), Toyoko Oguri (6), Alexandra Atkins (7), Nicole Turcotte (7), Richard Keefe (7), Shyama Brewster (8), Daniel K. Burns (8), Yuka Maruyama (8), Natali Zhukova (3), Irina Zhukova (3), Valentina Markova (3), Larisa Mihaycheva (3), Stepan Buikin (3), Zara Melikyan (8), Allen D. Roses (8) for the TOMMORROW study investigators  
(1) Joseph and Kathleen Bryan ADRC, Duke University Medical Center (Durham, NC); (2) Department of Psychiatry, Duke University Medical Center (Durham, NC); (3) Center for Clinical Trials, Nebbiolo LLC (Tomsk, RU); (4) Department of Social Sciences and Health Policy, Wake Forest School of Medicine (Winston-Salem, NC); (5) Takeda Development Center, Americas, Inc., (Deerfield, IL); (6) Covance Inc (Princeton NJ); (7) NeuroCog Trials Inc. (Durham, NC); (8) Zinfandel Pharmaceuticals, Inc. (Chapel Hill, NC)

### **P1-52 SOLCOS BASED-MODEL INDIVIDUAL REMINISCENCE FOR OLDER ADULTS WITH MILD TO MODERATE DEMENTIA IN RESIDENTIAL CARE: AN SECOND PILOT STUDY**

Peter Van Bogaert RN (1), MSc, PhD, Roel Eerlingen (1) RN, MSc, Daisy Carvers RN (1)  
(1) Division of Nursing and Midwifery Sciences, Centre for Research and Innovation in Care (CRIC), Faculty of Medicine and Health Sciences, University of Antwerp, Belgium

# POSTER PRESENTATIONS

## POSTER SESSION 1: Thursday, November 5<sup>th</sup>

### P1-53 ALZHEIMER'S DISEASE PREVENTION INTO PRIMARY CARE

Bertrand Fougère, MD, PhD (a,b), Bruno Chicoula, MD (c), Julien Delrieu, MD (a), Nédá Tavassoli, PhD (a,d), Christine Lagourdette (a), Julie Subra, MD (c), Stéphane Oustric, MD (b,c), Bruno Vellas, MD, PhD (a,b,d)  
(a) *Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France*; (b) *Inserm UMR1027, Université de Toulouse III Paul Sabatier, Toulouse, France*; (c) *Département de médecine générale, Université de Toulouse, France*; (d) *Equipe Régionale Vieillesse et Prévention de la Dépendance, Centre Hospitalier Universitaire de Toulouse, France*

### P1-54 NORMATIVE STUDY OF THE ITALIAN-LANGUAGE TOMMORROW NEUROCOGNITIVE BATTERY

Brenda L. Plassman, PhD (1,2), Samantha Galluzzi, MD (3), Carlo de Lenalena, MD (4), Kathleen A. Welsh-Bohmer, PhD (1,2), Heather Romero, PhD (1,2), Kathleen M. Hayden, PhD (1,2,5), Kumar Budur, MD, MS (6), Grant Runyan, PhD (6), Janet O'Neil, MBA (6), Stephen Crawford, PhD, MHS (7), Mark Atkinson, PhD (7), Toyoko Oguri, MS (7), Alexandra Atkins, PhD (8), Nicole Turcotte, MA (8), Richard Keefe, PhD (2,8), Shyama Brewster, BSc (Hons) (9), Dominic Fitzsimmons, BSc (Hons) (10), Daniel K. Burns, PhD (9), Maura Parapini, MS (3,11), Letizia Imbriano, MSc (4), Giovanni B. Frisoni, MD (3,11), Allen D. Roses, MD (9) for the TOMMORROW Study Investigators  
(1) *Joseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC, USA*; (2) *Department of Psychiatry, Duke University Medical Center, Durham, NC, USA*; (3) *IRCCS Fatebenefratelli, Brescia, Italy*; (4) *Department of Neurology and Psychiatry, Sapienza University of Rome, Italy*; (5) *Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA*; (6) *Takeda Development Center Americas, Inc., Deerfield, IL, USA*; (7) *Covance Inc, Princeton, NJ, USA*; (8) *NeuroCog Trials, Durham, NC, USA*; (9) *Zinfandel Pharmaceuticals, Inc., Chapel Hill, NC, USA*; (10) *Takeda Development Centre Europe Ltd, London, UK*; (11) *University Hospitals and University of Geneva, Geneva, Switzerland*

### P1-55 CULTURAL ADAPTATION OF THE TOMMORROW COGNITIVE BATTERY IN RUSSIA, SWITZERLAND, AND ITALY

Alexandra S. Atkins, PhD (1), Adam W. Vaughan, PhD (1), Nicole M. Turcotte, MA (1), Oksana A. Makeeva, PhD (2), Andreas U. Monsch, PhD (3), Giovanni B. Frisoni, MD (4,10), Maura Parapini, MS (10), Irina Zhukova, MD, PhD (2), Zara Melikyan, PhD (5), Shyama Brewster, BSc Joint (Hons) (5), Kumar Budur, MD, MS (6), Janet O'Neil, MBA (6), Heather R. Romero, PhD (8), Brenda L. Plassman, PhD (7,8), Kathleen M. Hayden, PhD (7,8,9), Kathleen A. Welsh-Bohmer, PhD (7,8), Richard S.E. Keefe, PhD (1,8)  
(1) *NeuroCog Trials, Durham, NC, USA*; (2) *Neuropsychology Testing Center, Nebbiolo, LLC, Tomsk, RU*; (3) *University Center for Medicine of Aging Basel, Felix Platter Hospital, Basel, CH*; (4) *IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, IT*; (5) *Zinfandel Pharmaceuticals Inc., Chapel Hill, NC, USA*; (6) *Takeda Development Center Americas, Inc., Deerfield, IL, USA*; (7) *Joseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC, USA*; (8) *Dept. of Psychiatry, Duke University Medical Center, Durham, NC, USA*; (9) *Dept. of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA*; (10) *University Hospitals and University of Geneva, Geneva, CH*

### P1-56 INTERNATIONAL NOMENCLATURE CONSENSUS WORKING PARTY: PERIOPERATIVE NEUROCOGNITIVE DISORDERS (PREVIOUSLY KNOWN AS POSTOPERATIVE DELIRIUM AND POSTOPERATIVE COGNITIVE DYSFUNCTION)

Lis Evered BSc, MBIostat, PhD (1,2), Steven DeKosky (3), Rod Eckenhoff (4), David Scott (1,2), Esther Oh (5), Greg Crosby (6,7), Brendan Silbert (1,2), and the international nomenclature consensus working party  
(1) *St Vincent's Hospital, Melbourne*; (2) *University of Melbourne*; (3) *University of Florida*; (4) *University of Pennsylvania*; (5) *Johns Hopkins Medicine*; (6) *Brigham and Women's Hospital, Boston*; (7) *Harvard Medical School*

### P1-57 COMPREHENSIVE COGNITIVE TRAINING IN LATER ADULTHOOD LEADS TO A REDUCTION IN ANNUALIZED AGE-RELATED COGNITIVE DECLINE

Daniel Sternberg, PhD1, Michael Scanlon, Glenn Morrison, MSc, PhD1  
(1) *Lumos Labs, Inc. San Francisco, CA*

## THEME 7: Clinical Trials and Behavioral Disorders

### P1-58 DEMENTIA IN LONG TERM CARE FACILITIES; TELEMEDICINE FOR THE MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS: THE DETECT STUDY. METHODS OF A CLUSTER RANDOMIZED CONTROLLED TRIAL

Maria Soto, MD, PhD (1), Antoine Piau, MD (2), Adelaide de Mauléon, MD (1), Pierre Rumeau, MD, PhD (1), Alsane Sene, PhD (2), Pascal Saidlitz MD (1), Benoit Lepage MD, PhD (3), Maryline Duboué, MSc (1), Bruno Vellas, MD, PhD (1), Fati Nourhashémi, MD, PhD (1)  
(1) *Gerontopôle, INSERM U 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, France*; (2) *Gerontopôle, Cand University, France*; (3) *Department of Epidemiology and Public Health, CHU Toulouse University Hospital, France, INSERM U 1027*

### P1-59 RATIONALE AND PRELIMINARY DATA FOR THE ADCS MULTICENTER TRIAL: PRAZOSIN FOR AGITATION IN ALZHEIMER'S DISEASE

Murray A. Raskind, MD (1,2), Elaine R. Peskind, MD (1,2), Lucy Wang, MD (1,2)  
(1) *VA Puget Sound Health Care System, Mental Illness Research, Education and Clinical Center (MIRECC), Seattle/American Lake, WA, USA*; (2) *University of Washington, Department of Psychiatry and Behavioral Sciences, Seattle, WA, USA*

# POSTER PRESENTATIONS

## POSTER SESSION 1: Thursday, November 5<sup>th</sup>

**P1-60** **APATHY AS A DRUG TARGET AND A SURROGATE MARKER IN AD CLINICAL TRIALS**  
Anton Alvarez, MD, PhD (1,2)  
(1) *Medinova Institute of Neurosciences, Clinica RehaSalud, A Coruña, Spain*; (2) *Clinical Research Department, QPS Holdings, A Coruña, Spain*

**P1-61** **RELATIONSHIP BETWEEN “CAREGIVER’S STRESS” AND BPSD IN NURSING HOMES**  
Alba Malara, MD (1), Francesco Bettarini MD (1), Francesco Ceravolo, MD (1), Serena Di Cello, MD (1), Francesco Praino, MD (1), Vincenzo Settembrini, MD (1), Giovanni Sgrò, MD (1), Fausto Spadea, MD (1), Vincenzo Rispoli, PhD (1)  
*Scientific Committee of National Association of Nursing Home for Third Age (ANASTE) Calabria, Lamezia Terme (CZ), Italy*

**P1-62** **DEPRESSION AND COGNITIVE DECLINE: FACTORS RELATED TO DEMOGRAPHICS AND PSYCHOPHARMACOTHERAPY ON ELDERLY IN NURSING HOMES**  
Edvaldo Soares, PhD, Patrícia de Souza Rossignoli, PhD  
*Laboratory of Cognitive Neuroscience-LaNeC, Sao Paulo State University, São Paulo, Brazil*

### THEME 11: Clinical Trials and New Therapies

**P1-63** **PROTEOTOXIC CONTROL IN ALZHEIMER’S DISEASE MAY BE ATTAINED BY BUBR1: A POSSIBLE TARGET FOR THERAPY?**  
Vladan Bajic (1), Biljana Spremo-Potparevic (2), Lada Zivkovic (2), Boban Stanojevic (3), Martina Bruckner (4), Thomas Arendt (4)  
(1) *Department of Radiobiology and Molecular Genetics, “Vinca” Institute, Belgrade, Serbia*; (2) *Department of Physiology, Faculty of Pharmacy, University of Belgrade, Serbia*; (3) *Department of Endocrinology and Molecular Biology, “Vinca” Institute, Belgrade, Serbia*; (4) *Paul-Flechsig-Institute for Brain Research, University of Leipzig, Medical Faculty, Leipzig, German*

**P1-64** **EFFICACY AND SAFETY OF A NOVEL ACETYLCHOLINESTERASE INHIBITOR OCTOHYDROAMINOACRIDINE IN MILD TO MODERATE ALZHEIMER’S DISEASE: A PHASE II MULTICENTER RANDOMIZED CONTROLLED TRIAL**  
Shifu Xiao (1,2), Tao Wang (1,2), Xia Li (1,2), Zhongxin Zhao (3), Xueyuan Liu (4), Xiaoping Wang (5), Hengge Xie (6), Qinqu Jiang (7), Li Sun (8), Benyan Luo (9), Lan Shang (10), Weixian Chen (11), Yan Bai (12), Muni Tang (13), Maolin He (14), Kaixiang Liu (15), Qilin Ma (16), Zhi Song (17), Yingyi Qin (18), Xiuqiang Ma (18), Jia He (18)  
(1) *Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China*; (2) *Alzheimer’s Disease and Related Disorders Center, Shanghai Jiao Tong University, Shanghai, China*; (3) *Department of Neurology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China*; (4) *Department of Neurology, the 10th People’s Hospital, Tongji University, Shanghai, China*; (5) *Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China*; (6) *Department of Geriatric Neurology, Chinese PLA General Hospital, Beijing, China*; (7) *Mental Health Center of Hebei Province, Baoding, Hebei Province, China*; (8) *Department of Neurology, the First Hospital of Jilin University, Changchun, Jilin Province, China*; (9) *Department of Neurology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China*; (10) *Beijing Hui-Long-Guan Hospital, Peking University, Beijing, China*; (11) *Department of Geratology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China*; (12) *First Affiliated Hospital of Kunming Medicine University, Kunming, Yunnan Province, China*; (13) *Guangzhou Psychiatric Hospital, Guangzhou, Guangdong Province, China*; (14) *Department of Neurology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China*; (15) *Affiliated Hospital of Guilin Medical School, Guilin, Guangxi Province, China*; (16) *Department of Neurology, the First Affiliated Hospital of Xiamen University, Xiamen, Fujian Province, China*; (17) *Neurological Department, the Third Xiangya Hospital of Central South University, Hunan Province, China*; (18) *Department of Health Statistics, Second Military Medical University, Shanghai, China*

**P1-65** **COMBINATION TRIALS WITH AMYLOID MODULATING AGENTS. A QUANTITATIVE SYSTEMS PHARMACOLOGY PERSPECTIVE**  
Hugo Geerts, PhD, BachMed (1,2); Athan Spiros, PhD (1)  
(1) *In Silico Biosciences, Berwyn, PA*; (2) *Perelman School of Medicine, Univ of Pennsylvania, Philadelphia, PA*

**P1-66** **RAMCIP PROJECT: ROBOTIC RESEARCH DEVELOPMENT TO HELP ALZHEIMER’S DISEASE PATIENTS AT HOME**  
Carla Abdelnour MD (1), Natalia Tantinyà (1), Joan Hernández MSc (1), Elvira Martín MSc (1), Silvia García (1), Joan Carles Ribes (1), Asunción Lafuente MD (1), Isabel Hernández MD, PhD (1), Maitee Rosende MD (1), Ana Mauleón MD (1), Liliانا Vargas MD (1), Montserrat Alegret PhD (1), Ana Espinosa MSc (1), Gemma Ortega PhD (1), Domingo Sánchez MD (1), Octavio Rodríguez MD (1), Pilar Canyabate PhD (1), Mariola Moreno (1), Silvia Preckler (1), Ángela Sanabria MSc (1), Alba Pérez-Cordón MSc (1), Lluís Tàrraga MSc (1), Agustín Ruiz MD, PhD (1), Mercé Boada MD, PhD (1), RAMCIP group  
(1) *Research Center and Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain*



# POSTER PRESENTATIONS

## POSTER SESSION 1: Thursday, November 5<sup>th</sup>

### **P1-67 SAFETY AND PHARMACOKINETICS OF ANTI-PROTOfIBRILLAR MAB SAR228810 IN FIRST-IN-MAN STUDY AFTER SINGLE AND MULTIPLE ASCENDING IV AND SC DOSING IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE**

Bruno Vellas, MD (1), Raphael Dahmen, MD (2), Olivier Nicolas, PhD (3), Valerie Martin, MS (4), Caroline Cohen, PhD (4), Laurent Vermet, MSc (3), Jérôme Barakos, MD (5), Joyce Suhy, PhD (5), Anne Börjesson-Hanson, MD (6), Henrik Östlund, MD (7), Geert Jan Groeneveld, MD (8), Niels Prins, MD (9), Philip Scheltens, MD (9), Kaj Blennow, MD (10), Niels Andreasen, MD (11) (1) *Gérontopôle, CHU Purpan, Toulouse, France*; (2) *Sanofi-Aventis R&D, Frankfurt, Germany*; (3) *Sanofi-Aventis R&D, Montpellier, France*; (4) *Sanofi-Aventis R&D, Chilly-Mazarin, France*; (5) *BioClinica, Medical Imaging, Newark, CA, USA*; (6) *Department of Neuropsychiatry, Sahlgrenska University Hospital, Gothenburg, Sweden*; (7) *Memory Clinic, Skanes University Hospital, Malmö, Sweden*; (8) *Centre for Human Drug Research, Leiden, the Netherlands*; (9) *Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands*; (10) *Clinical Neurochemistry Lab, Dept. of Neuroscience and Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden*; (11) *KI Alzheimer Center, Dept. of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden*

### **P1-68 SAFETY OF THE 5-HT<sub>6</sub> ANTAGONIST, RVT-101 IN PATIENTS WITH ALZHEIMER'S DISEASE: SUMMARY OF PHASE 2 CLINICAL TRIALS**

Ilise Lombardo, MD (1), Geetha Ramaswamy MD (1), Stephen C Piscitelli, PharmD (2), Lawrence T Friedhoff, MD, PhD, FACP (1) (1) *Axovant Sciences, Inc., New York, NY*; (2) *Roivant Sciences, Inc., New York, NY*

### **P1-69 STEM CELLS FOR ALZHEIMER'S DISEASE: TRANSITION TO CLINICAL TRIALS**

Tristan Bolmont, PhD (1,2), Theo Lasser (1), Alexei Lukashev, PhD (2), Nikolai Tankovich, MD, PhD (3) (1) *Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland*; (2) *Stemedica International, Epalinges, Switzerland*; (3) *Stemedica Cell Technologies, San Diego, CA, USA*

### **P1-70 PHARMACOGENETICS SUPPORTED CLINICAL TRIAL TO DELAY ONSET OF MCI DUE TO AD USING PIVOGLITAZONE 0.8 MG SR: TOMMORROW STUDY**

Kumar Budur, MD, MS (1), Kathleen A. Welsh-Bohmer, PhD (2), Daniel K. Burns, PhD (3), Carl Chiang, PhD (3), Janet O'Neil, MBA (1), Grant Runyan, PhD (1), Meredith Culp, BS (1), Donna G. Crenshaw, PhD (3,4), Michael W. Lutz, PhD (2), Craig A. Metz, PhD (3), Ann M. Saunders, PhD (2), Deborah Yarbrough, MS, MBA (1), Stephen Haneline, MS (3), David Yarnall, MS (3), Eric Lai, PhD (1), Stephen K. Brannan, MD (1), Allen D. Roses, MD (2,3) (1) *Takeda Development Center Americas, Inc., Deerfield, IL, USA*; (2) *Duke Bryan ADRC, Durham, NC, USA*; (3) *Zinfandel Pharmaceuticals, Inc., Research Triangle Park, NC, USA*; (4) *Department of Medicine, Duke University, Durham, NC, USA*

## POSTER SESSION 2: Friday, November 6<sup>th</sup>

### THEME 3: Clinical Trials Imaging

### **P2-1 CORTICAL THINNING PATTERNS IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE**

Eun Ye Lim (1), Jung Hee Cho (1), Yong Soo Shim (1), Yun Jeong Hong (2), Bora Yoon (3), Dong Won Yang (1) (1) *Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea*, (2) *Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea*, (3) *Konyang University College of Medicine, Daejeon, Korea*

### **P2-2 GRAY MATTER VOLUMES AND TREATMENT RESPONSE OF PSYCHOTIC SYMPTOMS TO RISPERIDONE IN ANTIPSYCHOTIC-NAÏVE ALZHEIMER'S DISEASE PATIENTS**

YoungMin Lee, PhD; Je-Min Park, MD, PhD, Byung-Dae Lee MD, PhD., Eunsoo Moon MD, Hee-Jeong Jeong, MD (1) *Department of Psychiatry, School of Medicine, Pusan National University, Busan, Korea*

### **P2-3 WHITE MATTER MICROSTRUCTURE DISRUPTION IS CORRELATED WITH AMYLOID BURDEN IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. FUNDACIO ACE HEALTHY BRAIN INITIATIVE**

O. Rodriguez-Gomez (1) MD, A. Sanabria (1) Msc, A. Pérez-Cordón (1) Msc, D. Sánchez-Ruiz MD (1), S. Ruiz (1), M. Tarragona (1), J. Pavía (2) PhD, F. Campos (2) Msc, A. Vivas (3) MD, M. Gómez (3) MD, M. Tejero (3) RT, M. Alegret (1) PhD, A. Espinosa (1) Msc, G. Ortega (1) PhD, C. Abdelnour (1) MD, I. Hernández (1) MD PhD, A. Ruiz (1) MD PhD J. Giménez (3) MD, F. Lomeña (2) MD, L. Tárraga (1) Msc, O. Sotolongo-Grau (1) PhD, M. Boada (1) MD PhD (1) *Alzheimer Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain*; (2) *Servei de Medicina Nuclear, Hospital Clínic i Provincial. Barcelona, Spain*; (3) *Departament de Diagnòstic per la Imatge. Clínica Corachan, Barcelona, Spain*

### **P2-4 PET STUDIES WITH RVT-101 IN HEALTHY VOLUNTEERS DEMONSTRATE HIGH OCCUPANCY OF THE 5HT<sub>6</sub> RECEPTOR**

Ilise Lombardo, MD (1), Geetha Ramaswamy, MD (1), Stephen C. Piscitelli, PharmD (2), Lawrence Friedhoff, MD, PhD, FACP (1) (1) *Axovant Sciences, Inc.*; (2) *Roivant Sciences, Inc.*